Healthcare Jan 13, 2022 10:05 AM (GMT+8) · EqualOcean
On January 13, yiouda health learned that West Lake Oumi (Hangzhou) Biotechnology Co., Ltd. completed a pre-A round of financing of hundreds of millions of yuan. This round of financing was jointly led by Yifeng capital and old shareholder Gaoling venture capital, followed by power capital, old shareholder Gaorong capital and West Lake Science and technology venture capital, The financing funds will continue to promote the research and development of in vitro assisted diagnosis (IVD) products driven by protein mass spectrometry and AI pharmaceutical products. Founded in July 2020, Xihu Omei is committed to developing and applying proteomics technology based on protein mass spectrometry. At present, West Lake Oumi has established a professional team with interdisciplinary background, including high-tech talents in the fields of biotechnology, artificial intelligence and drug R & D. At the same time, West Lake OMI has a number of patented technologies, established wholly-owned subsidiaries Hangzhou OMI medical laboratory Co., Ltd. and Hangzhou OMI Zhizao Biotechnology Co., Ltd., signed strategic cooperation memoranda with mass spectrometry manufacturers such as SCIEX, Thermo Fisher and Bruker, and became the exclusive agent and service provider of pressure Biosciences Inc. in China. At present, West Lake Oumi has established close cooperative relations with more than 70 top hospitals, scientific research institutions and pharmaceutical factories at home and abroad.

This text is a result of machine translation.